Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Treasury Shares of $1.5 million for Q1 2026, up 26.88% year-over-year from $1.2 million in Q1 2025, and up 14.13% quarter-over-quarter from $1.3 million in Q4 2025.
Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Treasury Shares for 8 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 26.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 26.88% YoY), while the FY2025 annual figure was $1.3 million, up 79.45% from the prior year.
- Treasury Shares grew to $1.5 million in Q1 2026 per KYMR's latest filing, from $1.3 million in the prior quarter.
- Across five years, Treasury Shares topped out at $1.5 million in Q1 2026 and bottomed at $121504.0 in Q1 2022.
- Historically, Treasury Shares has averaged $746263.2 across 5 years, with a median of $636585.0 in 2024.
- Annual changes were most pronounced in 2022 — Treasury Shares surged 646.7% — and 2024, when it rose 26.38%.
- Kymera Therapeutics' Treasury Shares stood at $281843.0 in 2022, then jumped by 110.45% to $593140.0 in 2023, then rose by 26.38% to $749604.0 in 2024, then soared by 79.45% to $1.3 million in 2025, then advanced by 14.13% to $1.5 million in 2026.
- Business Quant data shows KYMR's Treasury Shares at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Jun 30, 2026 | 1.53 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 749,604.00 |
| Dec 31, 2024 | 749,604.00 |
| Sep 30, 2024 | 783,295.00 |
| Sep 30, 2024 | 783,295.00 |
| Jun 30, 2024 | 636,585.00 |
| Jun 30, 2024 | 636,585.00 |
| Mar 31, 2024 | 725,438.00 |
| Mar 31, 2024 | 725,438.00 |